Global Biologics Contract Development Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Cell Line Development(Microbial, Mammalian and Others, Process Development(Upstream[Microbial, Mammalian and Others], Downstream[Impurity, isolation, & identification, Physicochemical characterization, Pharmaceutical analysis, and Others], and By Product[MABs, Recombinant proteins and Others].

By Source;

Mammalian, Microbial, Others.

By Indication;

Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn952728082 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Biologics Contract Development Market (USD Million), 2021 - 2031

In the year 2024, the Global Biologics Contract Development Market was valued at USD 8,537.54 million. The size of this market is expected to increase to USD 15,407.59 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.8%.

Biologics, which include a wide range of products such as vaccines, monoclonal antibodies, and cell and gene therapies, are complex molecules derived from living organisms. This complexity necessitates specialized expertise and infrastructure for development and manufacturing, leading many pharmaceutical and biotechnology companies to outsource these processes to contract development and manufacturing organizations (CDMOs). The collaboration with CDMOs allows companies to leverage advanced technologies, reduce time-to-market, and focus on core competencies such as research and marketing.

The biologics contract development market is bolstered by continuous advancements in bioprocessing technologies, regulatory support for biosimilars, and the growing trend towards personalized medicine. The rise of biosimilars, in particular, has created opportunities for CDMOs to provide development services for more cost-effective biologic alternatives. The increasing prevalence of chronic diseases and the aging global population drive the demand for innovative biologic therapies, further fueling market growth. As a result, the global biologics contract development market is expected to continue its robust expansion, with key players investing in capacity expansions, strategic collaborations, and technological innovations to meet the evolving needs of the pharmaceutical and biotechnology industries.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Source
    3. Market Snapshot, By Indication
    4. Market Snapshot, By Region
  4. Global Biologics Contract Development Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising prevalence of chronic diseases
        2. Advancements in biologics research and development
        3. Growing demand for personalized medicine
        4. Increased outsourcing by pharmaceutical companies
      2. Restraints
        1. Complex manufacturing processes
        2. Stringent regulatory requirements
        3. Supply chain challenges
      3. Opportunities
        1. Technological advancements in biomanufacturing
        2. Increasing collaborations and partnerships
        3. Rising adoption of biosimilars
        4. Development of novel biologic therapies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Biologics Contract Development Market, By Product, 2021 - 2031 (USD Million)
      1. Cell Line Development
        1. Microbial
        2. Mammalian
        3. Others
      2. Process Development
        1. Upstream
          1. Microbial
          2. Mammalian
          3. Others
        2. Downstream
          1. Impurity isolation & identification
          2. Physicochemical characterization
          3. Pharmaceutical analysis
          4. Others
        3. By Product
          1. Monoclonal Antibodies (MAbs)
          2. Recombinant Proteins
          3. Others
    2. Global Biologics Contract Development Market, By Source, 2021 - 2031 (USD Million)
      1. Mammalian
      2. Microbial
      3. Others
    3. Global Biologics Contract Development Market, By Indication, 2021 - 2031 (USD Million)
      1. Oncology
      2. Immunological Disorders
      3. Cardiovascular Disorders
      4. Hematological Disorders
      5. Others
    4. Global Biologics Contract Development Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape Analysis
    1. Company Profiles
      1. Wuxi Biologics
      2. Abzena Ltd.
      3. FUJIFILM Diosynth Biotechnologies
      4. KBI Biopharma
      5. AGC Biologics
      6. Genscript
      7. BioNova Scientific
      8. Almac Group
      9. Lakepharma, Inc
  7. Analyst Views
  8. Future Outlook of the Market